retrovector encoding mutant anti-cyclin G1: Clinical Trials

5 trials of retrovector encoding mutant anti-cyclin G1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 withdrawn. 5 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Withdrawn 2
Phase 25Completed 3, Withdrawn 2

Follow retrovector encoding mutant anti-cyclin G1: new trials by email Literature Review of retrovector encoding mutant anti-cyclin G1 trials Research Report on retrovector encoding mutant anti-cyclin G1

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
DeltaRex-G - COVID-19, Cytokine Storm
Phase 1 / Phase 2WithdrawnAveni Foundation2022-12-122025-02-24
Safety and Efficacy Study Using Rexin-G for Sarcoma
Rexin-G - Sarcoma
Phase 1 / Phase 2CompletedEpeius Biotechnologies362007-07-012011-06-10
Safety and Efficacy Study Using Rexin-G for Breast Cancer
Rexin-G - Breast Cancer
Phase 1 / Phase 2CompletedEpeius Biotechnologies202007-07-012011-06-10
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
Rexin-G - Pancreatic Cancer
Phase 1 / Phase 2CompletedEpeius Biotechnologies202007-07-012011-06-10
Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver
Mx-dnG1 Retroviral Vector - Colorectal Neoplasms
Phase 1 / Phase 2WithdrawnUniversity of Southern California2002-11-012014-05-22

Conditions studied

Breast Neoplasms (1)  ·  COVID-19 (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Cytokine Release Syndrome (1)  ·  Pancreatic Neoplasms (1)  ·  Respiratory Distress Syndrome (1)  ·  Sarcoma (1)

Sponsors

Epeius Biotechnologies (3)  ·  Aveni Foundation (1)  ·  University of Southern California (1)

Countries

United States (3)

Top investigators

Sant P Chawla, M.D. (3)  ·  Howard W Bruckner, M.D. (2)  ·  Sant P Chawla, MD (1)